Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis

Company Overview

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $0.83 to $0.92
• 50-Day Range: $0.57 to $0.90
• 52-Week Range: $0.53 to $5.21
• Volume: 1.02 million shs
• Average Volume: 1.40 million shs
• Market Capitalization: $145.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.94
• Consensus Rating: Hold

Ironwood Pharmaceuticals Stock Analysis - MarketRank™

Ironwood Pharmaceuticals scored higher than 89% of companies evaluated by MarketBeat, and ranked 109th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Ironwood Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Ironwood Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 150.00%

Earnings Growth

Earnings for Ironwood Pharmaceuticals are expected to grow by 150.00% in the coming year, from $0.10 to $0.25 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ironwood Pharmaceuticals is -17.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ironwood Pharmaceuticals is -17.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.19% of the float of Ironwood Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Ironwood Pharmaceuticals has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ironwood Pharmaceuticals has recently decreased by 12.70%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ironwood Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Ironwood Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.4 / 5
• Environmental Score: -2.94

Percentage of Shares Shorted

4.19% of the float of Ironwood Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Ironwood Pharmaceuticals has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ironwood Pharmaceuticals has recently decreased by 12.70%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.99

News Sentiment

Ironwood Pharmaceuticals has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Ironwood Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for IRWD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

8 people have added Ironwood Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ironwood Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.70% of the stock of Ironwood Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

IRWD Stock Analysis - Frequently Asked Questions

How have IRWD shares performed this year?

Ironwood Pharmaceuticals' stock was trading at $4.43 at the start of the year. Since then, IRWD shares have decreased by 79.8% and is now trading at $0.8969.

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) posted its earnings results on Thursday, August, 7th. The biotechnology company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of ($0.02) by $0.16. The biotechnology company had revenue of $85.24 million for the quarter, compared to analysts' expectations of $62.02 million. Ironwood Pharmaceuticals had a negative trailing twelve-month return on equity of 2.45% and a negative net margin of 2.25%.

Who are Ironwood Pharmaceuticals' major shareholders?

Top institutional investors of Ironwood Pharmaceuticals include Acadian Asset Management LLC (4.05%), Geode Capital Management LLC (2.16%), Connor Clark & Lunn Investment Management Ltd. (1.36%) and Los Angeles Capital Management LLC (0.75%). Insiders that own company stock include Thomas A Mccourt, Michael Shetzline, Mark G Currie, Jason Rickard, Sravan Kumar Emany, Andrew Davis, Minardo John, Ronald Silver, Julie Mchugh, Jon R Duane and Catherine Moukheibir.
View institutional ownership trends.

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ironwood Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ironwood Pharmaceuticals investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 8/08/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IRWD
• CIK: 1446847
• Web: www.ironwoodpharma.com
• Phone: (617) 621-7722
• Fax: 617-494-0480
• Employees: 220
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Ironwood Pharmaceuticals: $4.94
• High Price Target: $14.00
• Low Price Target: $0.70
• Potential Upside/Downside: +450.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 8.97
• P/E Growth: N/A
• Net Income: $880 thousand
• Net Margins: -9.89%
• Pretax Margin: 7.54%
• Return on Equity: -1.87%
• Return on Assets: -3.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.34
• Quick Ratio: 3.34

Sales & Book Value

• Annual Sales: $351.41 million
• Price / Sales: 0.41
• Cash Flow: $0.06 per share
• Price / Cash Flow: 16.27
• Book Value: ($1.88) per share
• Price / Book: -0.48

Miscellaneous

• Outstanding Shares: 161,820,000
• Free Float: 141,269,000
• Market Cap: $145.14 million
• Optionable: Optionable
• Beta: 0.33